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Pharmacogenetics by Wendell W. Weber represents the most
recent, most comprehensive book on this rapidly changing sub-
ject. “Pharmacogenetics,” a term first coined by Friedrich Vo-
gel (Heidelberg) in 1959, is the study of the hereditary basis
of the differences in responses to drugs. Werner Kalow (To-
ronto) and Arno Motulsky (Seattle) are especially to be cred-
ited for their public advocacy in this field during the past 4
decades. Ecogenetics is the broader field of interindividual dif-
ferences in response to all environmental, chemical, and phys-
ical agents (e.g., insecticides, compounds formed during com-
bustion, heavy metals, and ultraviolet radiation and x-rays).
Weber’s book includes some human ecogenetic disorders (e.g.,
cigarette smoking–induced bronchogenic carcinoma, arylam-
ine-induced bladder cancer, and susceptibility to beryllium tox-
icity), as well as most of the known pharmacogenetic disorders.
It is now clear that each of us has his or her own “individual
fingerprint” of unique alleles encoding the so-called drug-me-
tabolizing enzymes (DMEs) and the receptors that regulate
these enzymes. After the explosion of molecular biology and
human genetics during the past decade, this book therefore
provides us with a glimpse of where the field is today, almost
40 years after the term “pharmacogenetics” was first used.
Pharmacogenetics has grown out of Weber’s ∼30 years of
seminars, discussion, and teaching to upper-level undergrad-
uates, graduate students, and other students of the health sci-
ences, at the University of Michigan. I know this well because,
on many occasions over the past 20 years, I have been invited
by my good friend and colleague to participate in this teaching
at Ann Arbor.
The book is divided logically into two parts. Part I (“Phar-
macogenetic Concepts”) covers the emergence and broad scope
of the field, from a historical perspective, whereas part II (“Ap-
plications of Pharmacogenetic Concepts”) provides the exper-
imental epidemiological evidence and clinical cases for 33 hu-
man phenotypes of pharmacogenetic significance.
In part I, the chapters on historical perspective (“Begin-
nings”) and on dose-response relationships and pharmacoki-
netics (“Human Drug Response”) represent an excellent fast-
moving introduction to the field. In contrast, chapter 3 (“He-
redity”) is a bit “user unfriendly” and, in my opinion, may
turn off a lot of students because an excess of mathematical
equations is listed. Chapter 3 does provide, however, an ex-
cellent chronological overview of how pharmacogenetic dif-
ferences have been studied in fraternal versus identical twins,
how monogenic traits were first exploited, and how the con-
sensus that many pharmacogenetic diseases represent multi-
plex phenotypes caused by two or more genes—that is, that
they are polygenic—has now emerged.
The book has some problems in describing basic funda-
mentals of genetics. In particular, the concept of additive in-
heritance is covered incorrectly. For example, in table 3-6 (p.
51), at least eight traits listed as “manifesting autosomal re-
cessive inheritance” are in fact inherited additively. Moreover,
the text states that “four patterns of inheritance are commonly
observed within human families. These are autosomal domi-
nant, autosomal recessive, sex-linked dominant, and sex-
linked recessive” (p. 50). There is no mention in the text of
additive (codominant or gene-dose) inheritance until page 136
(“pedigree analysis of ALDH1 in hair root follicles [Goedde
et al., 1985] suggests an autosomal codominant mode of in-
heritance”). Yet, ample data in the subsequent text support
numerous examples of autosomal additive inheritance of phar-
macogenetic differences (e.g., plasma isoniazid concentrations
[fig. 3-7, p. 62]; the inheritance of a1-antitrypsin deficiency
[p. 218]; glucocorticoid-induced glaucoma [p. 309]; loss of one
or both glutathione-transferase alleles [table 6-18, p. 207]; the
paraoxonase [PON] gene and PON activities [tables 6-13, p.
179, and 6-14, p. 180]; the CHE1 gene encoding serum cho-
linesterase [p. 182]; and thiopurine methyltransferase activity
[fig. 6-11, p. 212]). The statement “genetic susceptibility to
the insulin-resistant state is a rare trait that is inherited poly-
genically” (p. 255; italics added) is inconsistent with the two
paragraphs on the genetic aspects of the insulin-receptor gene,
leading me to conclude that Weber had intended this as an
example of polyallelic inheritance. There are also several dis-
tracting examples of vague or nonstandard terms, such as “al-
lelic gene” (p. 185) and “gene loci” (p. 204).
Chapter 4 (“Drugs and Genes”) attempts to cover all aspects
of James D. Watson’s Molecular Biology of the Gene and, to
me, appears to be unwarranted in a book about pharmaco-
genetics. For example, do readers of this book really need to
know that human chromosome 2 is 277 cM in length (table
4-1, p. 72)? Is an illustration (fig. 4-1, p. 76) of the human
mitochondrial “DNA genome” [sic] relevant to the subject of
this book? That DNA is a helix (fig. 4-2, p. 77), that mRNA
is derived from exons after introns have been removed, and
that protein is translated from mRNA are facts that are now
presented to high-school students. Chapter 4 is the least in-
teresting and least essential part of the book.
Chapter 5 (“Experimental Models”) represents a return to
excellence. There is an outstanding description of the devel-
opment of congenic mouse lines and their relevance to phar-
macogenetics (a subject near and dear to Weber and to me).
There is one important typo (p. 117): in the book, “formyl-
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acetoacetate hydrolase” (italics added) should have been writ-
ten as fumarylacetoacetate hydrolase (encoded by the FAH
gene). The chapter ends with the most recent concepts on how
to generate knockout and other transgenic mouse lines and on
how to use “quantitative trait linkage (QTL) mapping” in the
elucidation of pharmacogenetic disorders. These discussions
are absolutely first-rate.
Part II of the book is almost twice as long as part I. Each
chapter and section in part II is followed by short exercises
designed to demonstrate a pharmacogenetic principle or to
illustrate the application of concepts and techniques to phar-
macological problems; these exercises are drawn almost en-
tirely from observations (taken from the original literature)
representing authentic clinical situations.
On the whole, part II is excellent. It is a bit disappointing,
however, that, although the P450 cytochromes are discussed
at some length (pp. 131–133 and elsewhere), there are no
references citing the well-developed CYP gene–superfamily no-
menclature system or the continuously updated Website (http:
//drnelson.utmem.edu/homepage.html) on this subject. It also
is unfortunate that the CYP2D6 alleles “A, B, C, D, L,” et
cetera (p. 169) are described in this book published in 1997,
because a recommended standardized nomenclature system for
all the human CYP2D6 alleles was reported in early 1996 and
has already become widely accepted. Furthermore, it would
have been helpful to the student reader to learn that aldos-
terone synthase and steroid 11-b-hydroxylase (under “Glu-
cocorticoid-Remediable Aldosteronism,” pp. 222–225) are in
fact P450 cytochromes encoded by the CYP11B2 and
CYP11B1 genes, respectively.
It always has been debatable as to where to draw the line
regarding inclusion or exclusion of a human disease as a phar-
macogenetic defect. For example, if pyridoxine-responsive ane-
mia, fructose intolerance, and lactose intolerance are included
as “pharmacogenetic disorders,” then why not acatalasemia,
ceruloplasmin deficiency (Wilson disease), and Na-sensitive
hypertension? Likewise, cystic fibrosis, vasopressin resistance,
retinoic acid resistance/acute promyelocytic leukemia, and
thrombophilia are included in the book, whereas other dis-
orders (e.g., the CYP2A6-mediated coumarin 7-hydroxylase,
NAD(P)H:quinone oxidoreductase, and microsomal epoxide
hydrolase polymorphisms) are not included.
Last, I believe that the textbook could have been improved
if the reader had been given the opportunity to ponder why,
on an evolutionary basis, these human pharmacogenetic poly-
morphisms might have occurred in the first place (see Nebert
1997 and the references therein). It is now very clear that
DMEs and the DME receptors that control the levels of DMEs
first evolved for critical life functions (e.g., cell division, spor-
ulation, mating, homeostasis, electrolyte balance, differentia-
tion, apoptosis, and neuroendocrine functions); then, in ani-
mals, DMEs more recently expanded to include the role of
detoxification of dietary products, evolving plant metabolites
and, of course, drugs. Hence, the high allelic frequencies seen
for many DME genes, among individuals within any one ethnic
group, might represent the evolution of balanced polymor-
phisms that we presently cannot appreciate, such as improved
rates of implantation, prenatal growth and development, post-
natal health in response to dietary selective pressures, or even
resistance to bacterial or viral infections. Allelic frequencies in
DME genes that differ among ethnic groups also might reflect
differences in diet that have evolved over thousands of years.
Two recent examples of clinical diseases correlated with mu-
tations in a DME gene (encoding enzymes that have been com-
monly ascribed only to metabolizing drugs and other foreign
chemicals) further underscore the tenet that DMEs often mod-
ulate critical life processes. Mutations and deletions in the
microsomal aldehyde-dehydrogenase gene called “fatty-alde-
hyde dehydrogenase” (FALDH) have been shown to be the
cause of Sjo¨gren-Larsson syndrome, which is characterized by
mental retardation, spasticity, and ichthyosis, indicating the
importance of this enzyme in neurocutaneous homeostasis.
Mutations in the CYP1B1 gene appear to be responsible for
primary congenital glaucoma (buphthalmos), implying that
failure of the CYP1B1 enzyme to metabolize a specific endog-
enous substrate leads to this affliction. Perhaps this subject
(i.e., the real reason for the existence of DME genes and these
clinical polymorphisms) could have been used to replace the
naive chapter 4 of part I, or it could have been used as a third,
conclusion section.
All in all, however, this book is a worthwhile addition to
the shelves of all colleagues in the field. Pharmacogenetics
should serve, for the next several years, as an invaluable re-
source for helping to teach upper-level undergraduates, grad-
uate students, and other students of such health sciences as
medicine, pharmacy, and nursing.
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Oxford Medical Databases, version 2.0. By Robin Winter
and Michael Baraitser. Oxford: Oxford University Press,
1996. £395.00 each.
The London Dysmorphology Database has been my favorite
syndromology search program for many years, but I have never
found it particularly easy to use. When I have been away from
it for a few weeks, I always seem to forget exactly which key
to push to make it do what I want. I was, therefore, anxious
to tear open the shrink-wrap on this new Windows imple-
mentation to see if my old friend was now friendlier.
The version of Oxford Medical Databases (OMD) that I
